利用行政索赔数据评估TAVR随机临床试验结局与治疗效应:EXTEND研究
EXTEND研究将HiR和SURTAVI试验中≥65岁患者链接至Medicare住院索赔数据,比较索赔衍生结局与试验裁定结局在复现治疗效应上的表现。结果显示,两试验主要终点(全因死亡等)的效应大小与方向均被索赔数据复现,TAVR非劣效于SAVR的结论一致;但非致死性、非手术相关次要结局的一致性较差。
要点
- 索赔数据可复现TAVR试验主要终点的治疗效应大小与方向
- 基于索赔与裁定结局均显示TAVR非劣效于SAVR
- 非致死性非手术次要结局的索赔与裁定一致性较差
核心结论
- 在HiR和SURTAVI试验中,使用索赔数据确定主要终点可复现治疗效应的大小和方向。
- 非致死性和非手术相关次要结局的复现程度不如主要终点。
- 索赔数据替代裁定结局用于全因死亡和某些手术结局可能有效可行,但其他终点可能不太适合。
研究设计与样本
- 将HiR和SURTAVI试验中≥65岁成人链接至2011年1月1日至2016年12月31日的100% Medicare住院索赔数据。
- HiR链接600名参与者,链接率80.0%;SURTAVI链接1005名参与者,链接率60.5%。
- 比较TAVR与SAVR治疗组间主要和次要终点,分别使用试验裁定结局与索赔衍生结局,随访1年(HiR)或2年(SURTAVI)。
主要发现
- HiR中,主要终点全因死亡率在TAVR组为13.7%、SAVR组为16.4%(试验数据与索赔数据一致),试验数据HR 0.84(95%CI 0.65-1.09;P=0.33),索赔数据HR 0.86(95%CI 0.66-1.11;P=0.34;交互P=0.80)。
- HiR中,基于试验和索赔结局均显示TAVR相对SAVR非劣效(两者Pnoninferiority<0.001)。
- SURTAVI中,主要终点在TAVR组为12.9%、SAVR组为13.1%(试验数据;HR 1.08,95%CI 0.79-1.48;P=0.90),索赔数据为TAVR 11.3%、SAVR 12.5%(HR 1.02,95%CI 0.73-1.41;P=0.58;交互P=0.89)。
- SURTAVI中,基于试验和索赔数据均显示TAVR非劣效于SAVR(两者Pnoninferiority<0.001)。
- 手术相关次要结局(如主动脉瓣再干预、起搏器植入率)在试验与索赔数据间的一致性高于非手术结局(如卒中、出血、心源性休克)。
临床怎么用
- 对于全因死亡和某些手术相关结局,可考虑使用索赔数据替代裁定结局进行传统试验治疗比较。
- 非致死性和非手术相关次要结局可能不太适合用索赔数据替代裁定结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Whether passively collected data can substitute for adjudicated outcomes to reproduce the magnitude and direction of treatment effect observed in cardiovascular clinical trials is not well known. METHODS: We linked adults ≥65 years of age in the HiR (US CoreValve Pivotal High Risk) and SURTAVI trials (Surgical or Transcatheter Aortic Valve Replacement in Intermediate-Risk Patients) to 100% Medicare inpatient claims, January 1, 2011, to December 31, 2016. Primary (eg, death and stroke) and secondary trial end points were compared across treatment arms (eg, transcatheter aortic valve replacement [TAVR] versus surgical aortic valve replacement [SAVR]) using trial-adjudicated outcomes versus outcomes derived from claims at 1 year (HiR) or 2 years (SURTAVI). RESULTS: Among 600 linked HiR participants (linkage rate, 80.0%), the rate of the trial's primary end point of all-cause mortality occurred in 13.7% of patients receiving TAVR and 16.4% of patients receiving SAVR at 1 year by using both trial data (hazard ratio, 0.84 [95% CI, 0.65-1.09]; P=0.33) and claims data (hazard ratio, 0.86 [95% CI, 0.66-1.11]; P=0.34; interaction P value=0.80). Noninferiority of TAVR relative to SAVR was seen by using both trial- and claims-based outcomes (Pnoninferiority<0.001 for both). Among 1005 linked SURTAVI trial participants (linkage rate, 60.5%), the trial's primary end point was 12.9% for TAVR and 13.1% for SAVR using trial data (hazard ratio, 1.08 [95% CI, 0.79-1.48]; P=0.90), and 11.3% for TAVR and 12.5% for SAVR patients using claims data (hazard ratio, 1.02 [95% CI, 0.73-1.41]; P=0.58; interaction P value=0.89). TAVR was noninferior to SAVR when compared using both trial and claims (Pnoninferiority<0.001 for both). Rates of procedural secondary outcomes (eg, aortic valve reintervention, pacemaker rates) were more closely concordant between trial and claims data than nonprocedural outcomes (eg, stroke, bleeding, cardiogenic shock). CONCLUSIONS: In the HiR and SURTAVI trials, ascertainment of trial primary end points using claims reproduced both the magnitude and direction of treatment effect in comparison with adjudicated event data, but nonfatal and nonprocedural secondary outcomes were not as well reproduced. Use of claims to substitute for adjudicated outcomes in traditional trial treatment comparisons may be valid and feasible for all-cause mortality and certain procedural outcomes but may be less suitable for other end points.
引用
- Strom JB, Faridi KF, Butala NM, et al. Use of Administrative Claims to Assess Outcomes and Treatment Effect in Randomized Clinical Trials for Transcatheter Aortic Valve Replacement: Findings From the EXTEND Study. Circulation. 2020. PMID: 32436390. doi:10.1161/CIRCULATIONAHA.120.046159
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。